USE OF ADALIMUMAB FOR HIDRADENITIS SUPPURATIVA

HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN

L04 - Immunosuppressive agents

4CPS-150

BACKGROUND

Adalimumab is antibody against tumor necrosis factor-α currently indicated for moderate to severe hidradenitis suppurativa (HS).

PURPOSE

To assess effectiveness and safety of adalimumab in patients with HS.

MATERIAL AND METHODS

A retrospective study of patients with HS and treated with adalimumab was developed.

MEASURED VARIABLES: age, gender, previous treatment and regimen therapy

EFFECTIVENESS

- Primary endpoint: Hidradenitis Suppurativa Clinical Response (HiSCR): ≥75% reduction (AN75)
- Secondary endpoint: Hurley Stages: 3 clinical stages
  - The highest stages more severe
- Secondary endpoint: Hidradenitis Suppurativa-Physician’s Global Assessment (HS-PGA): 6 points range
  - From clear to very severe

RESPONSE TIME (weeks)

0 24 48

SAFETY

- Adverse reactions (RA)
- Withdrawal treatments

RESULTS

- Mean age: 43 (14-65) years.
- Previous treatment: infliximab in 12(40%) patients.
- Treatment regimen: 80 mg at week 0 followed by 40 mg at week 1, and 40 mg every other week via subcutaneous in 29 (93.6%) patients and 80 mg at week 0 followed by 40 mg weekly in 2 (6.4%) patients.
- Increments frequency: 8 patients to 40 mg weekly.
- RA: 26 episodes in 17 (54.8%) patients.
- Withdrawal treatments: 3 by RA:
  - 1 arthropathy
  - 1 abdominal pain
  - 1 vision disorder

- HiSCR (AN75): Baseline - Week 24 - Week 48
  - Baseline
  - Week 24: 85.7%
  - Week 48: 71.4%

- Hurley Stages: Baseline - Week 24 - Week 48
  - Baseline
  - Week 24: 85.7% Hurley-I
  - Week 48: 75% Hurley-I
  - 12.9% Hurley-II
  - 77.4% Hurley-III
  - 14.3% Hurley-III

- HS-PGA: Baseline - Week 24 - Week 48
  - Baseline
  - Week 24: 3.2% Minimal
  - Week 24: 6.4% Mild
  - Week 24: 0% Clear
  - Week 24: 19.4% Moderate
  - Week 24: 45.2% Severe
  - Week 24: 25.8% Very Severe
  - Week 48: 85.7% Clear
  - Week 48: 14.3% Severe
  - Week 48: 71.4% Clear
  - Week 48: 7.1% Moderate
  - Week 48: 3.6% Severe
  - Week 48: 17.9% Very severe

CONCLUSION

1. Adalimumab showed an improvement in clinical endpoints in the most patients with HS at week 24 and 48.
2. More than half of patients recorded RA, mainly abdominal pain and hyperglycemia.
3. Some RA leading to withdrawal treatments.